Protecting the tuberculosis drug pipeline: Stating the case for the rational use of fluoroquinolones

European Respiratory Journal

Volumn 40, Issue 4, 2012, Pages 814-822

  Migliori, Giovanni Battista ^a   Langendam, Miranda W ^c   D'Ambrosio, Lia ^a   Centis, Rosella ^a   Blasi, Francesco ^b   Huitric, Emma ^e   Manissero, Davide ^e   Van Der Werf, Marieke J ^c,d  

^a IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^e EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Drug resistance; Fluoroquinolones; Lower respiratory tract infections; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG CONTROL; DRUG EXPOSURE; DRUG RESISTANT TUBERCULOSIS; DRUG USE; EUROPEAN UNION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS;

EID: 84867121814     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00036812     Document Type: Review

References (46)

1. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: an imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
2. Leung E, Weil DE, Raviglione M, et al. The WHO policy package to combat antimicrobial resistance. Bull World Health Organ 2011; 89: 390-392.
3. Zumla A, Blasi F, Raviglione MC. Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. Eur Respir J 2012; 39: 802-804.
4. World Health Organization. Global Tuberculosis Control 2011. WHO/HTM/TB/2011.16. Geneva, World Health Organization, 2011.
5. Sotgiu G, Lange C, Centis R, et al. Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 2010; 36: 475-477.
6. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. Eur Respir J 2011; 37: 950-959.
7. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
8. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
9. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
10. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
11. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
12. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-1380.
13. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427. (Pubitemid 46372084)
14. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveil 2007; 12: E070517.1.
15. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
16. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005; 171: 699-706. (Pubitemid 40471139)
17. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
18. Migliori GB, Zellweger JP, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
19. Migliori GB, Sotgiu G, Blasi F, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J 2011; 38: 493-495.
20. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Resp J 2008; 31: 904-910.
21. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. (Pubitemid 41829947)
22. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect 2011; 17: Suppl. 6, E1-E59.
23. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance in Europe 2009. Stockholm, European Centre for Disease Prevention and Control, 2011.
24. European Centre for Disease Prevention and Control. Progressing towards TB elimination. Stockholm, European Centre for Disease Prevention and Control, 2010.
25. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd Edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
26. Isaakidis P, Cox GS, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PlosOne 2011; 6: e28066.
27. Sandgren A, Cuevas LE, Dara M, et al. Childhood tuberculosis: progress requires advocacy strategy now. Eur Respir J 2012 [Epub ahead of print DOI 10.1183/09031936.00187711].
28. World Health Organization, Stop TB Partnership. The Global Plan to Stop TB 2011-2015. Transforming the Fight Towards Elimination of Tuberculosis. WHO/HTM/STB/2010.2. Geneva, World Health Organization, 2010.
29. van den Boom M, Seita A, Ottmani S, et al. Finding the way through the respiratory symptoms jungle: PAL can help. Eur Respir J 2010; 36: 979-982.
30. Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systemic review and meta-analysis. Int J Infect Dis 2011; 15: e211-e216.
31. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10.
32. CHINAL. www3.cinahl.com/home.php Date last accessed: December 2010.
33. TRIP database. www.tripdatabase.com/ Date last accessed: December 2010.
34. World Health Organization. International Clinical Trials Registry Platform. www.who.int/ictrp/en/ Date last accessed: December 2010.
35. Wells GA, Shea BJ, O'Connell D, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. www.ohri.ca/programs/clinical-epidemiology\oxford.htm Date last accessed: December 2010.
36. Jeon CY, Calver AD, Victor TC, et al. Use of fluoroquinolone antibiotics leads to treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011; 15: 77-83.
37. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1451.
38. Park I-N, Hong S-B, Oh Y-M, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 319-324. (Pubitemid 46447441)
39. Wang J-Y, Lee L-N, Lai H-C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrobial Chemotherapy 2007; 59: 860-865. (Pubitemid 47073356)
40. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48: 1354-1360.
41. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis. The effect duration and timing of fluoroquinolone exposure. Am J Crit Care Med 2009; 180: 365-370.
42. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375: 2100-2109.
43. Stop TB Partnership. Working Group on New TB Drugs. Drug pipeline. www.newtbdrugs.org/pipeline.php Date last accessed: January 2012.
44. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
45. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011; 66: Suppl. 6, vi47-vi56.
46. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.